UBS Group
QNCX icon

UBS Group’s Quince Therapeutics QNCX Stock Holding History

UBS Group’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$56 Sell
3
-172
-98% -$34.5K ﹤0.01% 10192
2025
Q4 		$118K Buy
175
+168
+2,400% +$84.5K ﹤0.01% 6828
2025
Q3 		$2.4K Sell
7
-7
-50% -$2.33K ﹤0.01% 9176
2025
Q2 		$4.7K Buy
14
+10
+250% +$2.29K ﹤0.01% 9247
2025
Q1 		$939 Sell
4
-2
-33% -$611 ﹤0.01% 9612
2024
Q4 		$2.08K Buy
6
+4
+200% +$1.2K ﹤0.01% 9115
2024
Q3 		$373 Hold
2
– – ﹤0.01% 8972
2024
Q2 		$360 Sell
2
-1
-33% -$181 ﹤0.01% 8954
2024
Q1 		$536 Hold
3
– – ﹤0.01% 8496
2023
Q4 		$530 Sell
3
-30
-91% -$6.01K ﹤0.01% 8608
2023
Q3 		$7.47K Buy
33
+28
+560% +$7.32K ﹤0.01% 7230
2023
Q2 		$1.37K Buy
5
+3
+150% +$934 ﹤0.01% 7936
2023
Q1 		$507 Sell
2
-227
-99% -$44.4K ﹤0.01% 9001
2022
Q4 		$29.4K Buy
229
+62
+37% +$10.4K ﹤0.01% 7259
2022
Q3 		$44K Buy
167
+41
+33% +$15.6K ﹤0.01% 6475
2022
Q2 		$56K Sell
126
-2
-2% -$1.41K ﹤0.01% 5832
2022
Q1 		$158K Buy
128
+50
+64% +$68K ﹤0.01% 5548
2021
Q4 		$197K Sell
78
-7
-8% -$42.7K ﹤0.01% 5709
2021
Q3 		$1.56M Buy
85
+34
+67% +$541K ﹤0.01% 3805
2021
Q2 		$537K Sell
51
-128
-72% -$1.07M ﹤0.01% 4675
2021
Q1 		$1.29M Buy
179
+126
+238% +$907K ﹤0.01% 4000
2020
Q4 		$293K Sell
53
-49
-48% -$434K ﹤0.01% 4984
2020
Q3 		$1.02M Sell
102
-13
-11% -$118K ﹤0.01% 3623
2020
Q2 		$1.06M Sell
115
-15
-12% -$137K ﹤0.01% 3455
2020
Q1 		$1.19M Sell
130
-5
-4% -$49.4K ﹤0.01% 3208
2019
Q4 		$1.51M Buy
135
+51
+61% +$308K ﹤0.01% 3831
2019
Q3 		$418K Buy
84
+50
+147% +$308K ﹤0.01% 4709
2019
Q2 		$290K Buy
+34
New +$203K ﹤0.01% 4675

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group's QNCX Position: Q1 2026 in Review

UBS Group reduced its Quince Therapeutics (QNCX) stake by 98% in Q1 2026, selling an estimated $34.5K and leaving 3 shares worth $56. The position accounts for ﹤0.01% of the portfolio, ranked #10192.

UBS Group first reported a position in QNCX in Q2 2019 and has held it in 28 quarters since. The position peaked at $1.56M in Q3 2021. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • UBS Group held 3 shares of Quince Therapeutics worth $56 as of Q1 2026.
  • UBS Group sold 172 Quince Therapeutics shares in Q1 2026, an estimated $34.5K.
  • Quince Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10192 holding.
  • UBS Group first reported a position in Quince Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • UBS Group's Quince Therapeutics position peaked at $1.56M in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.